QQQ0.69%

Trending

SPCX1.45%

Info

home Symbol CAPRnews

Exchange: NASDAQ·Updated 12:15 PM EDT

CAPRCapricor Therapeutics Inc

$5.92

$1.08

(15.37%)

Today

News·This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward

EarningsAug 11

Mkt Cap$405.09M

Vol7.25M

News

all

press releases

This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward

Alliance Global said that the upcoming FDA advisory committee meeting now appears to be an ‘uphill battle’ for Capricor.

Stocktwits

More News

Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Capricor Therapeutics, Inc. (Capricor or the Company) (NASDAQ: CAPR) investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAPRICOR THERAPEUTICS, INC...

Business Wire

Nasdaq, S&P 500 Futures Slip As Korea Chip Shock Dents AI Memory Heavyweights Ahead Of Fed Decision: Why NVDA, SNDK, MU, APLD, SPCX, SLS, CAPR Are In Focus

Retail sentiment remains ‘bearish’ on SPY and deteriorated to ‘extremely bearish’ on QQQ, amid growing anxiety around technology stocks.

Stocktwits

CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever

Wall Street turned more cautious, with Roth, B. Riley and Cantor flagging elevated approval risk.

Stocktwits

US Stock Futures Retreat Amid Chip Pressure Even As Oil Pulls Back On Iran Optimism: APLD, CAPR, NVDA, AMKR In Focus

Markets are largely focused on pivotal earnings from major hyperscalers this week, including Amazon.com, Apple, Meta and Microsoft.

Stocktwits

Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation CAPR

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the...

Business Wire

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (Capricor or the Company) (NASDAQ: CAPR) on behalf of investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC...

Business Wire

CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’

The documents released by the FDA on Monday, ahead of an advisory committee meeting to review Capricor’s application for Deramiocel, have raised a divide among Wall Street experts over what to expect.

Stocktwits

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data

FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July 29.read more...

Benzinga

QUICK SPARK: Capricor Stock Dives 'Complete Fraud' Says Pharma Bro Martin Shkreli

Martin Shkreli accuses Capricor Therapeutics of fraud and predicts legal action against its CEO and consultant over patient data.read more...

Benzinga